Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, KinaRx is raising $1,000,000.00 in new funding. Sources indicate as part of senior management President, Mohammad Aman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About KinaRx
KinaRx is an early stage biotechnology company developing novel kinase inhibitors for cancer. Inspired by the desire to treat patients we are relentlessly focused on developing the next generation of kinase centric treatments, with better efficacy and selectivity profiles. By focusing on addressing the unmet medical need to provide treatments for patients who develop resistance to existing kinase inhibitors we are uniquely positioned for rapid market entry. Our founders have extensive Oncology experience in drug discovery, clinical development and commercialization and a passion to bring life extending medicine to patients in need.

To learn more about KinaRx, visit http://www.kinarx.com/

Contact:
Mohammad Aman, President
240-454-8940
https://www.linkedin.com/in/m-javad-aman-b214759/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved